• Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., posted U.S. net sales of ophthalmic drug Eylea (aflibercept) of $363 million for the third quarter, a 49 percent jump over the same period last year and topping consensus estimates of $350 million.